EICHOR
● Active Not Recruiting
TheraSphere With Durvalumab and Tremelimumab for HCC
Condition: Hepatocellular Carcinoma · Sponsor: Boston Scientific Corporation
About this study
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (36)
| University of Arizona- Banner Health | Tucson, Arizona, United States | — |
| University of California San Diego | San Diego, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Georgetown University | Washington D.C., District of Columbia, United States | — |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| University of Chicago Hospital | Chicago, Illinois, United States | — |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | — |
| University of Minnesota | Minneapolis, Minnesota, United States | — |
| Washington University (Barnes-Jewish Hospital) | St Louis, Missouri, United States | — |
| Columbia University Irving Medical Center | New York, New York, United States | — |
+ 24 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.